Profile data is unavailable for this security.
About the company
Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused on commercializing novel pharmaceuticals. The Company’s segments include Women’s Health, Dermatology, and International. The Women’s Health segment distributes women’s health branded products in the United States. This segment includes NEXTSTELLIS, ANNOVERA, BIJUVA, IMVEXXY and branded pre-natal vitamins. The Dermatology segment distributes established dermatology products in the United States. The International segment is engaged in the manufacture and sale of branded and generic pharmaceutical products globally and the provision of contract development and manufacturing services to third party customers. The Company's products include ACTIKERALL Solution, ASTRIX Capsules and Tablets, MAGNOPLASM Paste and SPLINTEX Splinter Removal Gel, and ANNOVERA Vaginal Ring, among others. Its subsidiaries include Mayne Pharma International Pty Ltd, Mayne Holdings US Inc, Mayne Pharma LLC, and others.
- Revenue in AUD (TTM)413.01m
- Net income in AUD-90.07m
- Incorporated2005
- Employees450.00
- LocationMayne Pharma Group Ltd1538 Main North Road, Salisbury SouthADELAIDE 5106AustraliaAUS
- Phone+61 88209-2666
- Fax+61 88281-0284
- Websitehttps://www.maynepharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inoviq Ltd | 959.32k | -6.93m | 46.46m | 85.00 | -- | 2.20 | -- | 48.43 | -0.0623 | -0.0623 | 0.0086 | 0.1497 | 0.0478 | 3.73 | 0.6725 | -- | -34.52 | -43.01 | -37.36 | -45.87 | 87.45 | 89.08 | -722.62 | -1,543.44 | 5.72 | -- | 0.022 | -- | 21.17 | 57.69 | -5.77 | -- | -- | -- |
| Medical Developments International Ltd | 39.06m | 94.00k | 51.26m | 68.00 | 541.67 | 0.9302 | 15.55 | 1.31 | 0.0008 | 0.0008 | 0.3469 | 0.4891 | 0.6221 | 1.06 | 5.31 | -- | 0.1497 | -16.68 | 0.1738 | -18.92 | 75.35 | 72.70 | 0.2407 | -47.08 | 3.33 | -- | 0.0349 | -- | 17.82 | 11.30 | 100.23 | -24.33 | -34.91 | -- |
| Neurizon Therapeutics Ltd | 1.88m | -16.59m | 64.04m | 52.00 | -- | 16.51 | -- | 34.03 | -0.0334 | -0.0334 | 0.0038 | 0.0056 | 0.2431 | -- | 203.57 | -- | -214.34 | -65.69 | -254.22 | -74.86 | -- | -- | -881.68 | -368.00 | -- | -- | 0.00 | -- | -- | -- | -86.45 | -- | -44.79 | -- |
| Radiopharm Theranostics Ltd | 3.63m | -38.34m | 77.97m | 14.00 | -- | 1.16 | -- | 21.46 | -0.0179 | -0.0179 | 0.0017 | 0.0189 | 0.0458 | -- | 0.6382 | 259,530.70 | -48.38 | -- | -59.58 | -- | 1.08 | -- | -1,055.27 | -- | -- | -7.52 | 0.00 | -- | 1,114.26 | -- | 20.04 | -- | -- | -- |
| Biome Australia Ltd | 18.49m | 214.66k | 91.27m | 30.00 | 440.86 | 19.35 | 199.88 | 4.94 | 0.0009 | 0.0009 | 0.0833 | 0.0212 | 1.83 | 2.39 | 5.14 | -- | 2.12 | -43.09 | 5.42 | -74.65 | 61.27 | 60.84 | 1.16 | -31.29 | 1.02 | 1.80 | 0.3966 | -- | 41.43 | 80.32 | 112.85 | -- | 2.18 | -- |
| Vita Life Sciences Ltd | 85.60m | 9.31m | 142.01m | 124.00 | 15.71 | 2.76 | 29.33 | 1.66 | 0.1655 | 0.1655 | 1.52 | 0.9427 | 1.20 | 2.30 | 6.65 | -- | 13.05 | 15.71 | 17.96 | 22.24 | 60.34 | 59.82 | 10.87 | 12.15 | 2.21 | -- | 0.0409 | 47.99 | 8.28 | 13.37 | -3.26 | 22.87 | 29.67 | 21.67 |
| Recce Pharmaceuticals Ltd | 7.70m | -21.43m | 170.62m | -- | -- | -- | -- | 22.14 | -0.0899 | -0.0899 | 0.0325 | -0.0106 | 0.8203 | -- | 25.91 | -- | -228.15 | -150.15 | -- | -318.01 | -- | -- | -278.12 | -340.57 | -- | -17.98 | 1.49 | -- | 47.14 | 46.35 | -21.33 | -- | 34.71 | -- |
| Starpharma Holdings Ltd | 5.85m | -9.99m | 205.76m | 50.00 | -- | 10.79 | -- | 35.17 | -0.024 | -0.024 | 0.014 | 0.0454 | 0.188 | 0.5663 | 0.9444 | -- | -32.10 | -26.74 | -39.68 | -32.74 | 79.08 | 75.64 | -170.77 | -259.38 | 3.95 | -- | 0.1122 | -- | -40.04 | -2.25 | -22.35 | -- | -19.60 | -- |
| Mayne Pharma Group Ltd | 413.01m | -90.07m | 212.86m | 450.00 | -- | 0.5749 | -- | 0.5154 | -1.14 | -1.19 | 5.22 | 4.56 | 0.3828 | 2.57 | 2.42 | 917,797.80 | -8.35 | -15.32 | -11.61 | -20.87 | 61.06 | 53.04 | -21.81 | -64.51 | 1.16 | -- | 0.1003 | -- | 4.44 | -2.04 | 46.58 | -- | -9.26 | -- |
| Botanix Pharmaceuticals Ltd | 5.76m | -86.40m | 221.64m | 1.00 | -- | 2.71 | -- | 38.50 | -0.0466 | -0.0466 | 0.0031 | 0.0415 | 0.0477 | 0.2477 | 3.48 | -- | -71.53 | -50.27 | -81.16 | -56.02 | 36.99 | -- | -1,500.65 | -1,888.17 | 2.87 | -- | 0.2226 | -- | 856.64 | 102.14 | -522.91 | -- | 63.43 | -- |
| Clinuvel Pharmaceuticals Ltd | 95.02m | 36.17m | 532.13m | 16.00 | 14.77 | 2.21 | 14.25 | 5.60 | 0.7177 | 0.7177 | 1.89 | 4.80 | 0.3779 | 0.1857 | 3.54 | -- | 14.39 | 17.33 | 16.06 | 19.40 | 98.10 | 101.95 | 38.07 | 38.23 | 9.34 | -- | 0.0022 | 7.22 | -0.5085 | 23.46 | 1.50 | 19.17 | -19.60 | 14.87 |
| Holder | Shares | % Held |
|---|---|---|
| Rubric Capital Management LPas of 15 Jan 2026 | 4.36m | 5.36% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 2.82m | 3.47% |
| First Sentier Investors RQI Pty Ltd.as of 07 Jan 2026 | 2.30m | 2.84% |
| Pictet Asset Management SAas of 30 Jun 2025 | 1.72m | 2.12% |
| First Sentier Investors (Australia) IM Ltd.as of 07 Jan 2026 | 1.39m | 1.71% |
| Vanguard Investments Australia Ltd.as of 31 Dec 2025 | 1.37m | 1.69% |
| MLC Investments Ltd.as of 04 Mar 2025 | 1.10m | 1.35% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 1.00m | 1.24% |
| Pictet Asset Management (Singapore) Pte Ltd.as of 30 Jun 2025 | 683.46k | 0.84% |
| DFA Australia Ltd.as of 31 Dec 2025 | 682.90k | 0.84% |
